Provided by Tiger Trade Technology Pte. Ltd.

Sionna Therapeutics

36.11
+0.86002.44%
Post-market: 36.110.00000.00%16:20 EST
Volume:440.03K
Turnover:15.93M
Market Cap:1.61B
PE:-22.71
High:38.20
Open:35.23
Low:34.87
Close:35.25
52wk High:45.00
52wk Low:7.26
Shares:44.63M
Float Shares:12.61M
Volume Ratio:0.94
T/O Rate:3.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5900
EPS(LYR):-15.9861
ROE:-28.07%
ROA:-19.45%
PB:5.01
PE(LYR):-2.26

Loading ...

Director Peter A. Thompson Reports Disposal of Sionna Therapeutics Inc. Common Shares

Reuters
·
Feb 05

OrbiMed Advisors LLC Reports Sale of Sionna Therapeutics Inc. Common Shares

Reuters
·
Feb 05

Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

GlobeNewswire
·
Feb 04

BTIG Remains a Buy on Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Feb 03

Major Stake Unloaded in Sionna Therapeutics Sparks Fresh Market Buzz

TIPRANKS
·
Jan 27

TPG GP A, LLC Reports Disposal of Sionna Therapeutics Inc. Common Shares

Reuters
·
Jan 27

Sionna Therapeutics Price Target Maintained With a $58.00/Share by BTIG

Dow Jones
·
Jan 14

Sionna Therapeutics Inc : Btig Raises Target Price to $58 From $50

THOMSON REUTERS
·
Jan 07

Sionna Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Jan 07

OrbiMed Advisors Reports Disposal of Sionna Therapeutics Inc. Common Shares

Reuters
·
Dec 30, 2025

Director Peter A. Thompson Reports Disposal of Sionna Therapeutics Inc. Common Shares

Reuters
·
Dec 30, 2025

Sionna Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
Dec 24, 2025

LifeSci Capital Initiates Coverage on Sionna Therapeutics With Outperform Rating, $60 Price Target

MT Newswires Live
·
Dec 23, 2025

OrbiMed Advisors LLC Reports Sale of Sionna Therapeutics Common Shares

Reuters
·
Dec 20, 2025

Director Peter A. Thompson Reports Disposal of Sionna Therapeutics Inc. Common Shares

Reuters
·
Dec 20, 2025

Chief Legal Officer Jennifer Fitzpatrick Reports Disposal of Sionna Therapeutics Inc. Common Shares

Reuters
·
Dec 10, 2025

Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says

MT Newswires Live
·
Dec 05, 2025

Sionna Therapeutics Shares Lower After RBC Downgrade

MT Newswires Live
·
Dec 02, 2025

Sionna Therapeutics Cut to Underperform From Sector Perform by RBC Capital

Dow Jones
·
Dec 01, 2025

RBC Downgrades Sionna Therapeutics to Underperform From Sector Perform, Keeps $24 Price Target, Speculative Risk

MT Newswires Live
·
Dec 01, 2025